Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.90, 262–267 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wolfs RC, O’Colmain BJ et al. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol.122, 532–538 (2004).
   PubMed Web of Science ®Google Scholar
• National Eye Institute. Glaucoma and optic neuropathies program. National Plan for Eye and Vision Research (2006).
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120, 701–713 (2002).
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol.121(1), 48–56 (2003).
   PubMed Web of Science ®Google Scholar
• Wahl J. Results of the collaborative initial glaucoma treatment study (CIGTS). Ophthalmologe102(3), 222–226 (2005).
   PubMedGoogle Scholar
• Anderson DR. Collaborative normal tension glaucoma study. Curr. Opin. Ophthalmol.14(2), 86–90 (2003).
   PubMedGoogle Scholar
• Kaufman PL, Gabelt BT. Future of IOP lowering medication for glaucoma therapy. In: Essentials in Ophthalmology. Stamper R, Grehn F (Eds). Heidelberg, Springer-Verlag, Germany 138–155 (2006).
   Google Scholar
• Stjernschantz J, Selén G, Ocklind A, Resul B. Effects of latanoprost and related prostaglandin analogs. In: Uveoscleral Outflow. Biology and Clinical Aspects. Alm A, Weinreb RN (Eds). Mosby-Wolfe Medical Communications, London, UK, 57–72 (1998).
   Google Scholar
• Giuffré G. The effects of prostaglandin F2a in the human eye. Graefe’s Arch. Clin. Exp. Ophthalmol.222, 139–141 (1985).
   PubMed Web of Science ®Google Scholar
• Lee P-Y, Shoo H, Xu L, Qu C-K. The effect of prostaglandin F2a on intraocular pressure in normotensive human subjects. Invest. Ophthalmol. Vis. Sci.29, 1474–1477 (1988).
   PubMed Web of Science ®Google Scholar
• Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol.111, 1351–1358 (1993).
   PubMed Web of Science ®Google Scholar
• Bito LZ, Stjernschantz J, Resul B, Miranda OC, Basu S. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2α analog, PhXA41 (latanoprost), for glaucoma management. J. Lipid Mediat.6, 535–543 (1993).
   PubMedGoogle Scholar
• Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology103(1), 138–147 (1996).
   PubMed Web of Science ®Google Scholar
• Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Ophthalmology103, 1916–1924 (1996).
   PubMed Web of Science ®Google Scholar
• Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv. Ophthalmol.47(Suppl. 1), S105–S115 (2002).
   PubMed Web of Science ®Google Scholar
• Hylton C, Robin AL. Update on prostaglandin analogs. Curr. Opin. Ophthalmol.14(2), 65–69 (2003).
   PubMedGoogle Scholar
• Grant WM. Tonographic method for measuring the facility and rate of aqueous flow in human eyes. Arch. Ophthalmol.44, 204–214 (1950).
   PubMedGoogle Scholar
• Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol.131, 19–24 (2001).
   PubMed Web of Science ®Google Scholar
• Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 α, on aqueous humor dynamics in human eyes. Ophthalmology100, 1297–1304 (1993).
   PubMed Web of Science ®Google Scholar
• Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME. Potential mechanism for the additivity of pilocarpine and latanoprost. Am. J. Ophthalmol.131(6), 722–728 (2001).
   PubMed Web of Science ®Google Scholar
• Poyer JF, Millar JC, Kaufman PL. Prostaglandin F2α effects on isolated rhesus monkey ciliary muscle. Invest. Ophthalmol. Vis. Sci.36, 2461–2465 (1995).
   PubMed Web of Science ®Google Scholar
• Tamm E, Lütjen-Drecoll E, Rohen JW. Age-related changes of the ciliary muscle in comparison with changes induced by treatment with prostaglandin F2a. An ultrastructural study in rhesus and cynomolgus monkeys. Mech. Ageing Dev51, 101–120 (1990).
   PubMed Web of Science ®Google Scholar
• van Alphen GWHM, Robinette SL, Macri FJ. Drug effects on ciliary muscle and choroid preparations in vitro.Arch. Ophthalmol.68, 111–123 (1962).
   Google Scholar
• Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segments of cynomolgus monkey eyes following treatment with prostaglandin F2a. Exp. Eye Res.47, 761–769 (1988).
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism – implications for uveoscleral outflow. Surv. Ophthalmol.41(Suppl. 2), S53–S59 (1997).
   PubMed Web of Science ®Google Scholar
• Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann. Pharmacother.36(3), 504–511 (2002).
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu W-P, Group. XS. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol.135, 688–703 (2003).
   PubMed Web of Science ®Google Scholar
• Law SK, Song BJ, Fang E, Caprioli J. Feasibility and efficacy of a mass switchfrom latanporst to bimatoporst in glaucoma patients in a prepaid Health Maintenance Orgainzation. Ophthalmology112(12), 2123–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Brittain CJ, Saxena R, Waldock A. Prospective comparative switch study from imolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%. Adv. Ther.23(1), 68–73 (2006).
   PubMedGoogle Scholar
• Takagi Y, Nakajima T, Shimazaki A et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp. Eye Res.78, 767–776 (2004).
   PubMed Web of Science ®Google Scholar
• Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am. J. Ophthalmol.136, 18–25 (2003).
   PubMed Web of Science ®Google Scholar
• Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J. Glaucoma11, 354–358 (2002).
   PubMedGoogle Scholar
• Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics24(3), 251–264 (2006).
   PubMed Web of Science ®Google Scholar
• Plosker GL, Keam SJ. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics24(3), 297–314 (2006).
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am. J. Ophthalmol.141(1 Suppl.), S15–S21 (2006).
   Google Scholar
• Soto J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with tother medications (correspondence). Pharmacoeconomics24(5), 519–520 (2006).
   PubMedGoogle Scholar
• Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin. Invest. Drugs10(4), 721–731 (2001).
   PubMed Web of Science ®Google Scholar
• Woodward DF, Krauss AH-P, Chen J et al. The pharmacology of bimatoprost (LumiganTM). Surv. Ophthalmol.45 (Suppl.), S337–S345 (2001).
   PubMed Web of Science ®Google Scholar
• Woodward DF, Krauss AH-P, Chen J et al. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024). J. Pharmacol. Exp. Ther.305, 772–785 (2003).
   PubMed Web of Science ®Google Scholar
• Krauss AH-P, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv. Ophthalmol.49(1), S5–S11 (2004).
   PubMed Web of Science ®Google Scholar
• Brandt JD, VanDenburgh AM, Chen K et al. Comparison of once-or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology108, 1023–1031 (2001).
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol.45(Suppl. 4), S347–S351 (2001).
   PubMed Web of Science ®Google Scholar
• Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology111, 1658–1662 (2004).
   PubMed Web of Science ®Google Scholar
• Higgenbotham EJ, Schuman JS, Goldberg I et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol.120, 1286–1293 (2002).
   PubMedGoogle Scholar
• Richter M, Krauss AH-P, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci.44, 4419–4426 (2003).
   PubMed Web of Science ®Google Scholar
• Camras CB, Toris CB, Sjoquist B et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology111, 2193–2198 (2004).
   PubMed Web of Science ®Google Scholar
• Davies SS, Ju W-K, Neufeld AH, Abran D, Chemtob S, Jackson Roberts L II. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro.J. Ocul. Pharmacol. Ther.19, 45–54 (2003).
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Boehm AG. Time course of aqueous humor levels of bimatoprost and its acid in humans. Invest. Ophthalmol. Vis. Sci. 47 (ARVO Abs), Abstract 1547 (2006).
   Google Scholar
• Cantor LB, Hoop J, WuDunn D et al. Levels of bimatoprost acid in the aqueous humour of cataract patients after bimatoprost treatment. Br. J. Ophthalmol. (2006). (Epub).
   Google Scholar
• Sjoquist B, Stjernschantz JW. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol.47(Suppl. 1), S6–S12 (2002).
   PubMed Web of Science ®Google Scholar
• Hellberg MR, Ke T-L, Haggard K, Klimko PG, Dean TR, Graff G. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2α by human and rabbit ocular tissues. J. Ocul. Pharmacol. Ther.19, 97–103 (2003).
   PubMedGoogle Scholar
• Dahlin D, Bergamini MVW, Curtis MA, Dean TR, Kiehlbauch CC, Chastain JE. Bimatoprost hydrolysis to 17-phenyl-trinor PGF2a by rabbit and monkey ocular tissues in vivo.Invest. Ophthalmol. Vis. Sci. 43 (ARVO abstracts), Abstract 4109 (2002).
   Google Scholar
• Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv. Ophthalmol.47(Suppl. 1), S34–S40 (2002).
   PubMed Web of Science ®Google Scholar
• Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future17, 691–704 (1992).
   Google Scholar
• Resul B, Stjernschantz J, No K et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J. Med. Chem.36, 243–248 (1993).
   PubMed Web of Science ®Google Scholar
• Chen J, Senior J, Marshall K et al. Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles. Br. J. Pharmacol.144, 493–501 (2005).
   PubMed Web of Science ®Google Scholar
• Matias I, Chen J, De Petrocellis L et al. Prostaglandin-ethanolamides (prostmides): in vitro pahrmcology and metabolism. J. Pharm. Exp. Ther.309, 745–757 (2004).
   PubMed Web of Science ®Google Scholar
• Koda N, Tsutsui Y, Niwa H, Ito S, Woodward DF, Watanabe K. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. Arch. Biochem. Biophys.424, 128–136 (2004).
   PubMed Web of Science ®Google Scholar
• Liang Y, Li C, Guzman VM et al. Upregulation of orphan nuclear receptor Nur77 follwoing PGF2a, bimatoprost, and butaprost treatments. Essential role of a protein kinase C pathway involved in EP2 receptor activated Nur77 gene transcription. Br. J. Pharmacol.142, 737–748 (2004).
   PubMed Web of Science ®Google Scholar
• Liang Y, Li C, Guzman VM et al. Comparison of prostaglandin F2a, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem.278, 27267–27277 (2003).
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology110, 609–614 (2003).
   PubMed Web of Science ®Google Scholar
• Eisenberg D. Latanoprost versus bimatoprost (letter). Ophthalmology110(9), 1861–1862 (2003).
   PubMedGoogle Scholar
• Gagliuso DJ, Wang R-F, Mittag TW, Podos SM. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Arch. Ophthalmol.122, 1342–1347 (2004).
   PubMedGoogle Scholar
• Sharif NA, Kelly CR, Williams GW. Bimatoprost (Lumigan®) is an agonist at the cloned human FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies. Prostagladins Leukot. Essent. Fatty Acids68, 27–33 (2003).
   PubMedGoogle Scholar
• Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogs. Invest. Ophthalmol. Vis. Sci.44, 715–721 (2003).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J. Ocul. Pharmacol. Ther.19, 437–455 (2003).
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther.19(6), 501–515 (2003).
   PubMed Web of Science ®Google Scholar
• Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest. Ophthalmol. Vis. Sci.46, 4571–4577 (2005).
   PubMed Web of Science ®Google Scholar
• Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analoques on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci.46, 4159–4163 (2005).
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology113, 239–246 (2006).
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Hennes EA, Bendel MA, Okka M, Kaufman PL. IOP lowering comparison in monkeys: PGF2a-ie vs the rest. Invest. Ophthalmol. Vis. Sci.47 (ARVO Suppl.), Abstract 217 (2006).
   Google Scholar
• Cantor LB, WuDunn D, Cartes A, Hoop J, Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv. Ophthalmol.49(Suppl. 1), S12–S18 (2004).
   PubMedGoogle Scholar
• Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM, Group BCIS. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol.49(Suppl. 1), S26–S35 (2004).
   PubMed Web of Science ®Google Scholar
• DuBiner H, Cooke D, Dirks MS, Stewart WC, van den Burgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv. Ophthalmol.45(4), S353–S360 (2001).
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin NT et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol.135, 55–63 (2003).
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L. A meta-analysis of randomized clinical trials comparing the efficacy and safety of latanoprost, travoprost, and bimatoprost in reducing the intraocular pressure. Invest. Ophthalmol. Vis. Sci.47(ARVO Abs), Abstract 423 (2006).
   Google Scholar
• Holmstrom S, Buchholz P, Walt J, Wickstrom J, Aagren M. Analytic review of bimatroprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin.21(11), 1875–1883 (2005).
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. A meta-analysis of randomized clinical trials. Ophthalmology112, 1177–1185 (2005).
   PubMed Web of Science ®Google Scholar
• Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv. Ther.21(4), 247–262 (2004).
   PubMed Web of Science ®Google Scholar
• Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv. Ther.19, 275–281 (2002).
   PubMed Web of Science ®Google Scholar
• Gandolfi SA, Cimino L. Latanoprost versus bimatoprost (reply). Ophthalmology110(9), 1862 (2003).
   PubMedGoogle Scholar
• Woodward DF, Nieves AL, Friedlander MH. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J. Pharmacol. Exp. Ther.279, 137–142 (1996).
   PubMed Web of Science ®Google Scholar
• Gomi K, Zhe FG, Marshall JS. Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through EP1/EP3-dependent mechanism. J. Immunol.165, 6545–6552 (2000).
   PubMed Web of Science ®Google Scholar
• Doi LM, Melo LAS Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial. Br. J. Ophthalmol.89, 547–549 (2005).
   PubMedGoogle Scholar
• Linden C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr. Eye Res.17, 567–572 (1998).
   PubMed Web of Science ®Google Scholar
• Herndon LW, Asrani SG, Williams GH, Challa P, Lee PP. Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch. Ophthalmol.120(6), 847–849 (2002).
   PubMed Web of Science ®Google Scholar
• Steinhauser SL. Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry77(4), 177–179 (2006).
   PubMedGoogle Scholar
• Hoyng PF, Rulo A, Greve E, Watson P, Alm A. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv. Ophthalmol.41(Suppl. 2), S93–S98 (1997).
   Web of Science ®Google Scholar
• Toris CB, Alm A, Camras CB. Latanoprost and cholinergic agonists in combination. Surv. Ophthalmol.47(1), S141–S147 (2002).
   Google Scholar
• Crawford K, Kaufman PL. Pilocarpine antagonizes PGF2α-induced ocular hypotension: evidence for enhancement of uveoscleral outflow by PGF2α. Arch. Ophthalmol.105, 1112–1116 (1987).
   PubMed Web of Science ®Google Scholar
• Toor A, Chanis RA, Polikoff LA, Fahim MM, Sinha AP, Serle JB. Additivity of pilocarpine to bimatoprost in ocular hypertesion and early glaucoma. J. Glaucoma14(3), 243–248 (2005).
   PubMedGoogle Scholar
• Kaufman PL. The prostaglandin wars (editorial). Am. J. Ophthalmol.136, 727–728 (2003).
   PubMed Web of Science ®Google Scholar
• Nilsson SF, Drecoll E, Lutjen-Drecoll E et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci.47(9), 4042–4049 (2006).
   PubMed Web of Science ®Google Scholar
• Kharlamb AB, Krauss AH, Chen J et al. Prostanoid EP4 receptor stimulation produces profound ocular hypotension that involves pressure dependent outflow. Invest. Ophthalmol. Vis. Sci.45(Suppl.), Abstract 1035 (2004).
   Google Scholar
• Bradley JM, Vranka J, Colvis CM et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci.39, 2649–2658 (1998).
   PubMed Web of Science ®Google Scholar
• Kee C, Sohn S, Hwang J-M. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo.Invest. Ophthalmol. Vis. Sci.42, 2856–2860 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao X, Pearson KE, Stephan DA, Russell P. Effects of prostaglandin analogs on human ciliary muscle and trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci.44, 1945–1952 (2003).
   PubMed Web of Science ®Google Scholar